What it said it expected, against what it reported
4 targets with a reported result
Above the range
4
above the last range given
Within the range
0
of 4 range targets
Below the range
0
below the last range given
The numbers IDXX said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Diluted EPS Fiscal 2026 |
Given $14.29 to $14.80 release 2026-02-02
Raised $14.45 to $14.90 release 2026-05-05
Raised $14.69 to $14.94 release 2026-08-04
Raised $14.96 to $15.16 release 2026-11-02
|
– | Not reported yet |
The company's wordsGrowth and Financial Performance Outlook 2026 … EPS $14.29 - $14.80 release 2026-02-02 Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of release 2026-05-05 Increases 2026 EPS outlook to $14.69 - $14.94, reflecting an increase of release 2026-08-04 Raises 2026 EPS outlook to $14.96 - $15.16, reflecting a $0.25 increase release 2026-11-02 | |||
| Revenue Fiscal 2026 |
Given $4.67B to $4.76B release 2026-05-05
Raised $4.70B to $4.75B release 2026-08-04
Raised $4.74B to $4.77B release 2026-11-02
|
– | Not reported yet |
The company's wordsIncreases 2026 revenue guidance to $4,675 million - $4,760 million, up release 2026-05-05 Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5 release 2026-08-04 Increases 2026 revenue guidance to $4,741 million - $4,767 million, up release 2026-11-02 | |||
| Diluted EPS Fiscal 2025 (ended 2025-12-31) |
Given $11.74 to $12.24 release 2025-02-03
Raised $11.93 to $12.43 release 2025-05-01
Raised $12.40 to $12.76 release 2025-08-04
Raised $12.81 to $13.01 release 2025-11-03
|
$13.08 10-K filed 2026-02-20 |
Above the range |
The company's wordsGrowth and Financial 2025 Performance Outlook … EPS $11.74 - $12.24 release 2025-02-03 Updates 2025 EPS outlook to $11.93 - $12.43, reflecting $0.19 increase to · EPS compared to prior guidance, supported by benefits from updated foreign exchange impacts and favorable adjustment to a now-concluded litigation matter expense accrual. release 2025-05-01 Updates 2025 EPS outlook to $12.40 - $12.76, reflecting $0.40 increase compared to · prior guidance midpoint, supported by increased revenue and operating profit margin outlook, a lower effective tax rate, as well as benefits from updated foreign exchange impacts. release 2025-08-04 Raises 2025 EPS outlook to $12.81 - $13.01, reflecting $0.33 increase release 2025-11-03 | |||
| Revenue Fiscal 2025 (ended 2025-12-31) |
Given $4.05B to $4.17B release 2025-02-03
Raised $4.09B to $4.21B release 2025-05-01
Raised $4.21B to $4.28B release 2025-08-04
Raised $4.27B to $4.30B release 2025-11-03
|
$4.30B 10-K filed 2026-02-20 |
Above the range |
The company's wordsProvides initial outlook for 2025 revenue of $4,055 million - $4,170 million, reflecting growth of release 2025-02-03 Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an · increase of $40 million or ~1% at midpoint, reflecting benefits of foreign exchange impacts updated from prior estimates. release 2025-05-01 Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increase of $90 million or ~2% at · midpoint, reflecting solid CAG Diagnostics recurring revenue performance, outlook for higher IDEXX inVue Dx™ instrument placements and revenues, and $70 million benefit of foreign exchange impacts versus prior estimates. release 2025-08-04 Increases 2025 revenue guidance to $4,270 million - $4,300 million, an release 2025-11-03 | |||
| Diluted EPS Fiscal 2024 (ended 2024-12-31) |
Given $10.84 to $11.33 release 2024-02-05
Lowered $10.82 to $11.20 release 2024-05-01
Lowered $10.31 to $10.59 release 2024-08-06
Narrowed $10.37 to $10.53 release 2024-10-31
|
$10.67 10-K filed 2025-02-21 |
Above the range |
The company's wordsGrowth and Financial Performance 2024 Outlook … EPS $10.84 - $11.33 release 2024-02-05 Updates 2024 EPS outlook to $10.82 - $11.20, representing 8% - 11% growth as release 2024-05-01 Adjusts 2024 EPS outlook to $10.31 - $10.59, a reduction of $0.56 per share at · midpoint reflecting impacts from the $0.56 per share discrete litigation expense accrual and consistent expectations for solid comparable operating margin improvement. release 2024-08-06 Narrows 2024 EPS outlook to $10.37 - $10.53, maintaining consistent EPS midpoint compared to prior guidance, supported by consistent outlook release 2024-10-31 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $0.16 release 2024-02-05
|
– | No standard number |
The company's wordsProjected 2024 comparable EPS growth outlined in the 2024 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year 2023 reported EPS adjusted for positive share-based compensation activity of $0.16 for full year 2023; and (ii) projected full year 2024 reported EPS adjusted for estimated positive share-based compensation activity of $0.10 and estimated positive year-over-year foreign currency exchange rate change impact of $0.02. release 2024-02-05 | |||
| Revenue Fiscal 2024 (ended 2024-12-31) |
Given $3.90B to $3.96B release 2024-05-01
Lowered $3.87B to $3.89B release 2024-10-31
|
$3.90B 10-K filed 2025-02-21 |
Above the range |
The company's wordsUpdates 2024 revenue guidance to $3,895 million - $3,965 million, reflecting 6.5% release 2024-05-01 Adjusts 2024 revenue guidance to $3,865 million - $3,890 million, a reduction of $38 million or ~1% at midpoint, incorporating expectations release 2024-10-31 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2023-11-01), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.